文献速递系统性红斑狼疮

在西班牙大型多中心系统性红斑狼疮队列中全面评估贝利尤单抗的有效性

Thorough assessment of the effectiveness of belimumab in a large Spanish multicenter cohort of systemic lupus erythematosus patients.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

这项纵向回顾性多中心队列纳入18个西班牙中心的324例接受贝利尤单抗治疗的SLE患者,中位随访3.8(±2.7)年,观察到LLDAS和DORIS 2021达标率随访视逐步升高, flares显著减少,泼尼松剂量显著降低且24%患者停用糖皮质激素,未观察到损伤累积变化。

要点

  • 贝利尤单抗治疗后LLDAS达标率在连续访视中分别为45.8%、62%和71%,DORIS 2021达标率分别为24%、36.2%和52.5%。
  • 治疗一年后flares及flares数量显著降低,且未观察到损伤累积变化。
  • 泼尼松平均剂量随时间显著降低,70例(24%)患者停用糖皮质激素。

核心结论

  • 贝利尤单抗不仅能在SLE患者中达到治疗目标,还证实其具有节省糖皮质激素、预防flares和器官损伤累积的作用。

研究设计与样本

  • 纵向回顾性多中心队列研究,纳入西班牙18个中心接受贝利尤单抗治疗的SLE患者324例,中位随访3.8(±2.7)年。

主要发现

  • LLDAS达标率在连续访视中分别为45.8%、62%和71%,DORIS 2021达标率分别为24%、36.2%和52.5%。
  • 27.2%的患者在≥50%的访视中处于DORIS达标状态,46%的患者处于LLDAS-50状态。
  • 治疗一年后flares及flares数量显著降低,未观察到损伤累积变化。
  • 泼尼松平均(±SD)剂量随时间显著降低,70例(24%)患者停用糖皮质激素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To provide an overview on the current use of belimumab (BLM) in SLE patients in clinical practice and to examine its efficacy in terms of standardized outcomes, drug survival, as well as patient and safety profiles. METHODS: A longitudinal retrospective multicenter cohort including SLE patients treated with BLM at 18 Spanish centers. Data was collected upon initiation of BLM, at 6 and 12 months after initiation, and at the last recorded visit. Changes in SLEDAI-2K, the proportion of patients who achieved LLDAS and DORIS 2021, and number of flares were compared between visits. Changes in damage, glucocorticoids use and employment status pre-BLM and post-BLM were also assessed. RESULTS: A total of 324 patients were included with a mean follow-up of 3.8 (±2.7) years. LLDAS was attained by 45.8%, 62% and 71% of patients, and DORIS by 24%, 36.2% and 52.5% on successive visits, respectively. A total of 27.2% of patients were in DORIS ≥50% of the visits and 46% in LLDAS-50. Flares and number of flares were significantly lower one year after treatment with BLM and no changes in damage accrual were observed. Mean (±SD) prednisone dose was significantly reduced over time, with 70 (24%) patients discontinuing GC. CONCLUSION: Our study not only demonstrates belimumab's efficacy in attaining treat-to-target goals in SLE patients, but also confirms its GC-sparing effect, and its prevention of flares and organ damage accrual.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Altabás-González I, Pego-Reigosa JM, Mouriño C, et al. Thorough assessment of the effectiveness of belimumab in a large Spanish multicenter cohort of systemic lupus erythematosus patients. Rheumatology (Oxford). 2025. PMID: 38490245. doi:10.1093/rheumatology/kead696

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。